［Abstract］　Transcatheter intervention for valvular heart disease, featuring in less invasiveness, was initially introduced for patients with surgical contraindications or at high surgical risk. High-quality randomized controlled trials have established its safety and effectiveness for the management of valvular heart disease compared to conventional surgeries or state-of-art medications. Over the past two decades, we have seen a large number of novel instruments and technological improvements on transcatheter valve therapy. Thus, the indications for transcatheter valve therapy have expanded, currently aiming at patients with low surgical risk or challenging anatomies, and the transcatheter valve therapy has achieved good preliminary results. In this paper, we investigate who are suitable for transcatheter intervention for valvular heart disease, based on the 2020 American College of Cardiogy(ACC)/American Heart Association(AHA) guideline for the management of patients with valvular heart disease and the latest literatures reviewing.]]> 2021/7/5 12:12:34 DU Yu, LIU Wei, ZHOU Yu-jie 6true ［Abstract］　Left bundle branch block(LBBB) is a common complication in patients with heart failure(HF). According to the pathophysiological process, if LBBB develops first and gradually induces left ventricle(LV) remodeling and hemodynamic deterioration, this type of HF is considered as “LBBB inducing HF”; if HF develops first, and then a subsequent complication of LBBB occurs, this type of HF is considered as “HF inducing LBBB”. For the former type of HF patients, after the LV activation sequence corrected by cardiac resynchronization therapy(CRT), the mechanical dyssynchrony and cardiac remodeling can be reversed and the patients will have good response to CRT; while for the latter type of HF patients, even though the activation sequence is corrected by CRT, underlying cardiomyopathy cannot be resolved and therefore it is likely that the patients will not respond to CRT. Cardiac magnetic resonance(CMR) tissue tracking can identify the unique abnormal movement of the septal wall and the preserved systolic function of left ventricular lateral wall in patients with “LBBB inducing HF”, while extensive myocardial dyskinesia can be recognized in patients with “HF inducing LBBB”. For patients with unclear medical history, if the left ventricular end-diastolic lateral wall/septal wall thickness ratio is greater than 0.93 and the left ventricular lateral wall thickening rate is greater than 21%, the patients can be considered as “LBBB inducing HF ”, on the contrary, the patients are considered as “ HF inducing LBBB”. CMR can provide predictive value for CRT response and provide an important basis for clinical selection of HF patients who are suitable for CRT.]]> 2021/7/5 12:12:34 CHANG San-shuai, DONG Jian-zeng 5true ［Abstract］　At present, the prevalence rate of heart failure(HF) in China is as high as 1.3%, about 13.7 million cases, and the 5-year survival rate of HF is less than 50%, which is equivalent to that of malignant tumors, bringing a heavy burden to the prevention and treatment of cardiovascular diseases in China. Sacubitril/valsartan is the first angiotensin receptor neprilysin inhibitor(ARNI) drug in the world. In 2017, sacubitril/valsartan was marketed in China. In 2018, sacubitril/valsartan was included in the Chinese Heart Failure Guidelines and recommended for patients suffering from heart failure with reduced ejection fraction(HFrEF). However, heart failure with preserved ejection fraction(HFpEF) accounts for about half of the HF population, and there is still a lack of drugs that can truly improve the prognoses of HFpEF patients.This situation was broken by the “Expanded Indications for the Treatment of Chronic Heart Failure with Sacubitril/Valsartan” approved by the United States Food and Drug Administration(FDA) on February 16, 2021. This paper interprets and summarizes the major research progress of sacubitril/valsartan in the field of HF in recent years, and focuses on the analysis of its evidence support in patients with HFpEF.]]> 2021/7/5 12:12:34 WANG Hong, LOU Qi, LI Wei-min 4true ［Abstract］　Heart failure(HF) is a complicated clinical syndrome caused by structural remodeling and functional impairment of the heart. The changes of heart structure and function are closely related to the etiology of HF. “One-stop” cardiac magnetic resonance imaging can provide non-invasive in-vivo assessment of cardiac structure, function, and histological features, which is of great importance in analysis of the etiology of HF.]]> 2021/7/5 12:12:34 YANG Ying-xia, LU Min-jie 3true ［Abstract］　In recent years, great advances have been made in the drug treatment of heart failure. Sodium-glucose cotransporter 2(SGLT2) inhibitors, a new class of insulin-independent hypoglycemic agents, can significantly reduce blood glucose and glycated hemoglobin levels in patients with type 2 diabetes. DAPA-HF and EMPEROR-Reduced studies published in recent years show that SGLT2 inhibitors significantly improve the prognoses of patients suffering from heart failure with reduced ejection fraction(HFrEF), regardless of the presence or absence of type 2 diabetes, eventually transforming the “Golden Triangle” foundational drug treatment of heart failure into the “fantastic four”, and making the drug-treatment idea of heart failure get innovation.]]> 2021/7/5 12:12:34 LIANG Zhi-shan, XU Zhi-meng, JI Qing-wei 2true ［Abstract］　Cardiac resynchronization therapy(CRT) is a kind of device therapy for chronic heart failure. It can correct ventricular systolic asynchrony, reverse ventricular remodeling, increase ejection fraction and improve clinical prognosis by pacing left and right ventricles simultaneously. Since the 1990s, CRT has been applied in clinic and has been widely used. However, it is difficult to popularize in primary hospitals due to its disadvantages such as difficult implantation, easy dislocation and high cost. His-Purkinje system pacing is a new cardiac pacing technique developed in recent years. Studies have showed that the clinical effect of His-Purkinje system pacing is similar to or even better than that of conventional CRT, bringing new hope for the pacing treatment of chronic heart failure. This paper reviews the research status of CRT and the application prospect of His-Purkinje system pacing in chronic heart failure.]]> 2021/7/5 12:12:34 LU Zheng-de, SHI Lei, HU Chang-xing 1true